Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Helix BioPharma Corp. Provides an Update on the U.S. Study of L-DOS47

AURORA, ON–(Marketwired – Apr 22, 2015) –  Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRES OR DISSEMINATION IN THE UNITED STATES First Patient Dosed and Three Clinical Sites Initiated Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of […]

Read More »

FDA Accepts Filing of BETACONNECT for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON (interferon beta-1b)

WHIPPANY, N.J., April 22, 2015 /PRNewswire/ — Bayer is pleased to announce today that the U.S. Food and Drug Administration (FDA) has accepted the filing for Bayer’s supplemental Biologics License Application (sBLA) for BETACONNECT TM (proposed name), another delivery option for BETASERON® (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis. “This filing underscores Bayer’s continued, longstanding […]

Read More »

Roche more confident in beating Alzheimer’s after Biogen data

(Reuters) – Swiss drugmaker Roche has “renewed confidence” that drugs targeting potentially brain-destroying plaque can fight Alzheimer’s disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O’Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer’s drugs, both of which suffered setbacks in 2014, in […]

Read More »

Extreme ‘morning sickness’ tied to children’s neurological problems

(Reuters Health) – The children born to women who suffered severe nausea and vomiting during pregnancy are more likely to be diagnosed with neurological developmental disorders, according to a small U.S. study. Compared to children of women without such severe morning sickness – formally known as hyperemesis gravidarum – children who were exposed to the […]

Read More »

Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis

CARLSBAD, Calif., April 22, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx.  An […]

Read More »

Recommended treatments for alcoholic hepatitis ‘fail to keep patients alive’

(Reuters) – Two key drugs recommended in international guidelines and used to treat alcoholic hepatitis are failing to increase patients’ survival and leave death rates among patients “alarmingly high”, researchers said on Wednesday. In a trial involving more than 1,000 patients, the generic medicines — prednisolone and pentoxifylline — were found to make no significant […]

Read More »

Acacia Pharma Initiates Phase 3 Combination Prophylaxis Study With APD421 in Post-Operative Nausea & Vomiting (PONV)

CAMBRIDGE, England, April 21, 2015 /PRNewswire/ — Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains […]

Read More »

Scientists to share real-time genetic data on deadly MERS, Ebola

(Reuters) – Genetic sequence data on two of the deadliest yet most poorly understood viruses are to be made available to researchers worldwide in real time as scientists seek to speed up understanding of Ebola and MERS infections. The project, led by British scientists with West African and Saudi Arabian collaboration, hopes to encourage laboratories […]

Read More »

International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson’s Disease in Cell Transplantation

CARLSBAD, CA–(Marketwired – April 21, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has published the results of two proof of concept studies that demonstrate the safety and efficacy of the company’s readily expandable stem cell derived […]

Read More »

Promising New Developments in the Fight Against Cancer From SHAL Technologies

Biotech Awarded NIH Grant to Continue Testing New Drugs to Treat Lymphomas and Leukemias LIVERMORE, CA–(Marketwired – April 21, 2015) – SHAL Technologies, an emerging biotech company in the San Francisco Bay Area, has been awarded a $1.5M Phase II SBIR grant by the National Cancer Institute of NIH to complete the preclinical testing of […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom